Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour Apellis Pharmaceuticals, Inc. (APLS), dont 17 achats et 30 ventes. Le total des achats d'initiés s'élève à $2.58M et le total des ventes d'initiés à $3.11M.

Les initiés notables ayant une activité récente comprennent Biogen Inc., Francois Cedric, Dolsten Mikael. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — APLS

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-03-31	Biogen Inc.	Other: See Footnotes	Inconnu	-	-	-	-
2026-03-11	Francois Cedric	Chief Executive Officer	Don (Reçu)	64,869	-	-	372,815
2026-03-02	Dolsten Mikael	Director	Inconnu	-	-	-	-
2026-02-27	Dolsten Mikael	Director	Attribution de RSU	14,312	-	-	14,312
2026-02-11	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	368	$22.15	$8.15K	114,591
2026-02-03	Francois Cedric	Chief Executive Officer	Exercice d'Options (Vente)	8,840	$3.76	$33.24K	-
2026-01-28	Watson David O.	General Counsel	Attribution de RSU	55,986	-	-	144,517
2026-01-28	Deschatelets Pascal	Chief Scientific Officer	Attribution de RSU	25,840	-	-	1,177,222
2026-01-28	Francois Cedric	Chief Executive Officer	Attribution de RSU	195,952	-	-	481,997
2026-01-28	Sullivan Timothy Eugene	Chief Financial Officer	Attribution de RSU	58,140	-	-	152,041
2026-01-28	Nicholson Nur	Chief Technical Officer	Attribution de RSU	45,220	-	-	116,338
2026-01-28	Chopas James George	VP/chief Accounting Officer	Attribution de RSU	16,150	-	-	65,955
2026-01-28	Delong Mark Jeffrey	Chief Business & Strat Officer	Attribution de RSU	36,606	-	-	114,959
2026-01-28	Boucher Kelley	Chief People Officer	Attribution de RSU	30,146	-	-	127,804
2026-01-28	Meltzer Leslie	Chief Research and Development	Attribution de RSU	45,220	-	-	107,024
2026-01-22	Watson David O.	General Counsel	Vente Informative	7,832	$21.77	$170.47K	88,531
2026-01-22	Deschatelets Pascal	Chief Scientific Officer	Vente Informative	5,928	$21.77	$129.03K	1,151,382
2026-01-22	Francois Cedric	Chief Executive Officer	Vente Informative	27,192	$21.77	$591.84K	286,045
2026-01-22	Sullivan Timothy Eugene	Chief Financial Officer	Vente Informative	10,287	$21.77	$223.9K	93,901
2026-01-22	Nicholson Nur	Chief Technical Officer	Vente Informative	7,725	$21.77	$168.14K	71,118
2026-01-22	Chopas James George	VP/chief Accounting Officer	Vente Informative	2,064	$21.77	$44.92K	49,805
2026-01-22	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	3,371	$21.77	$73.37K	78,353
2026-01-22	Baumal Caroline	Chief Medical Officer	Vente Informative	2,797	$21.77	$60.88K	86,527
2026-01-20	Watson David O.	General Counsel	Vente Informative	2,475	$19.79	$48.99K	96,363
2026-01-20	Deschatelets Pascal	Chief Scientific Officer	Vente Informative	909	$19.79	$17.99K	1,157,310
2026-01-20	Francois Cedric	Chief Executive Officer	Vente Informative	8,182	$19.79	$161.95K	313,237
2026-01-20	Sullivan Timothy Eugene	Chief Financial Officer	Vente Informative	2,892	$19.79	$57.24K	104,188
2026-01-20	Nicholson Nur	Chief Technical Officer	Vente Informative	2,203	$19.79	$43.6K	78,843
2026-01-20	Chopas James George	VP/chief Accounting Officer	Vente Informative	726	$19.79	$14.37K	51,869
2026-01-20	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	1,334	$19.79	$26.4K	81,724
2026-01-20	Baumal Caroline	Chief Medical Officer	Vente Informative	1,882	$19.79	$37.25K	89,324
2026-01-13	Watson David O.	General Counsel	Vente Informative	5,780	$22.19	$128.24K	98,838
2026-01-13	Deschatelets Pascal	Chief Scientific Officer	Vente Informative	2,277	$22.19	$50.52K	1,158,219
2026-01-13	Francois Cedric	Chief Executive Officer	Vente Informative	10,186	$22.19	$226K	321,419
2026-01-13	Sullivan Timothy Eugene	Chief Financial Officer	Vente Informative	3,856	$22.19	$85.55K	107,080
2026-01-13	Nicholson Nur	Chief Technical Officer	Vente Informative	2,618	$22.19	$58.09K	81,046
2026-01-13	Chopas James George	VP/chief Accounting Officer	Vente Informative	873	$22.19	$19.37K	52,595
2026-01-13	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	1,780	$22.19	$39.49K	83,058
2026-01-07	Watson David O.	General Counsel	Exercice d'Options (Vente)	888	$14.95	$13.28K	14,000
2026-01-05	Baumal Caroline	Chief Medical Officer	Vente Informative	3,020	$25.53	$77.1K	91,206
2026-01-01	Wheeler Craig A	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Machiels Alec	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Chan Gerald	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	O'brien Stephanie Monaghan	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Dunlop A. Sinclair	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Fonteyne Paul R.	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2026-01-01	Walbert Keli	Director	Attribution de RSU	14,684	$25.12	$368.86K	14,684
2025-12-16	Watson David O.	General Counsel	Vente Informative	5,000	$24.49	$122.45K	103,730
2025-11-17	Watson David O.	General Counsel	Vente Informative	5,000	$20.06	$100.3K	108,730
2025-10-21	Sullivan Timothy Eugene	Chief Financial Officer	Vente Informative	10,000	$28.03	$280.3K	110,936

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration